Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Shilpa Pharma, Inc. v. Novartis Pharmaceuticals Corporation
Case Number:
1:21-cv-00558
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
May 18, 2022
Novartis' DQ Bid Sinks In Gilenya Row
A federal judge in Delaware has rejected a legal effort to prevent a Washington, D.C., patent lawyer from representing an Indian pharmaceutical company in a patent fight with Novartis over the blockbuster multiple sclerosis drug Gilenya.
-
May 05, 2022
Novartis Can't DQ Rival's Atty In Drug IP Row, Report Says
A special master recommended Thursday that a Delaware federal court rebuff Novartis' bid to disqualify one of its competitor's attorneys in a drug patent suit over the multiple sclerosis treatment Gilenya, determining that it's unlikely the lawyer will be called to testify.
-
April 25, 2022
Novartis Wants Rival's Atty Booted From MS Drug Patent Suit
Novartis Pharmaceutical Corp. continued to argue that a lawyer representing Shilpa Pharma Inc. must be disqualified because his testimony as a witness will likely be "central" to a patent dispute in Delaware federal court over a multiple sclerosis drug.
-
December 14, 2021
Pharma Co. Seeks To Deny Novartis' 'Speculative' DQ Bid
Shilpa Pharma Inc. has asked the Delaware federal court to reject Novartis Pharmaceuticals Corp.'s bid to disqualify a lawyer representing Shilpa in a patent dispute over a multiple sclerosis drug, arguing Novartis' contention the attorney is conflicted is "speculative at best and completely baseless at worst."
-
November 24, 2021
Novartis Wants Atty DQ'd From MS Drug Patent Row In Del.
Novartis Pharmaceuticals Corp. asked a Delaware federal court to disqualify a lawyer representing another pharmaceutical company that has filed a patent infringement suit against it related to a multiple sclerosis drug, saying the attorney is a key witness in the litigation.